Revenue: US$28.8b (up 6.0% from FY 2023). Net income: US$480.0m (down 92% from FY 2023). Profit margin: 1.7% (down from 21% in FY 2023). EPS: US$0.39 (down from US$4.54 in FY 2023). Revenue ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Night - Scattered showers with a 83% chance of precipitation. Winds from NE to NNE at 6 to 7 mph (9.7 to 11.3 kph). The overnight low will be 35 °F (1.7 °C). Cloudy with a high of 34 °F (1.1 ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Night - Clear. Winds from NNW to N at 6 to 7 mph (9.7 to 11.3 kph). The overnight low will be 29 °F (-1.7 °C). Mostly sunny with a high of 51 °F (10.6 °C). Winds variable at 6 to 7 mph (9.7 to ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Gilead ...